Personalis, Inc. (NASDAQ:PSNL) Holdings Increased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its holdings in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 144.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 410,083 shares of the company's stock after acquiring an additional 242,141 shares during the period. Dimensional Fund Advisors LP owned approximately 0.58% of Personalis worth $2,372,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. abrdn plc acquired a new stake in shares of Personalis in the fourth quarter worth $1,722,000. Barclays PLC increased its position in shares of Personalis by 67.1% in the fourth quarter. Barclays PLC now owns 109,368 shares of the company's stock worth $632,000 after acquiring an additional 43,900 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Personalis in the fourth quarter worth $64,000. XTX Topco Ltd acquired a new stake in shares of Personalis in the fourth quarter worth $193,000. Finally, American Century Companies Inc. increased its position in shares of Personalis by 98.8% in the fourth quarter. American Century Companies Inc. now owns 50,321 shares of the company's stock worth $291,000 after acquiring an additional 25,011 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Guggenheim assumed coverage on shares of Personalis in a report on Thursday, May 15th. They set a "buy" rating and a $6.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price target on shares of Personalis in a report on Thursday, April 10th. HC Wainwright raised their price target on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, May 7th. Finally, Craig Hallum initiated coverage on shares of Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $7.67.

Personalis Stock Performance

Shares of Personalis stock traded down $0.11 during trading hours on Tuesday, reaching $4.91. The company's stock had a trading volume of 27,145 shares, compared to its average volume of 1,004,206. The company's 50 day simple moving average is $3.79 and its 200 day simple moving average is $4.45. Personalis, Inc. has a one year low of $1.14 and a one year high of $7.20. The stock has a market cap of $433.68 million, a P/E ratio of -2.92 and a beta of 1.83.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $20.61 million for the quarter, compared to the consensus estimate of $17.41 million. On average, sell-side analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.